Inactive Instrument

All News Sarepta Therapeutics Inc Nasdaq

Equities

US0023461041

End-of-day quote Nasdaq Other stock markets
- ^USD	-

02/05	Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says	MT
02/05	UBS Adjusts Price Target on Sarepta Therapeutics to $173 From $167, Maintains Buy Rating	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sarepta Therapeutics - Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health	06/05	AQ
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health	03/05	BU
Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says	03/05	MT
UBS Adjusts Price Target on Sarepta Therapeutics to $173 From $167, Maintains Buy Rating	02/05	MT
Morgan Stanley Raises Price Target on Sarepta Therapeutics to $165 From $160, Keeps Overweight Rating	02/05	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 EPS $0.73, vs. Street Est of $0.30	02/05	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 Revenue $413.5M, vs. Street Est of $370.5M	02/05	MT
Sarepta Therapeutics Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Rise After Hours	02/05	MT
Transcript : Sarepta Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024	02/05
Sarepta Therapeutics: Q1 Earnings Snapshot	02/05	AQ
Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments	02/05	BU
Sarepta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/05	BU
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results	24/04	BU
REGENXBIO And Sarepta Agree To Stay Litigation Pending Outcome Of Sarepta's IPR Petition	04/04	AQ
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - March 29, 2024	01/04	AQ
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	30/03	BU
FDA greenlights Italfarmaco's drug for rare muscular dystrophy	22/03	RE
Sarepta Therapeutics Announces Call for Applications for the 2024 LGMD Grant Award Program	20/03	AQ
Transcript : Sarepta Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:05 PM	13/03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Sarepta Therapeutics Inc Nasdaq

Equities

US0023461041

All News

Filters